News from the healthcare data industry
People with different ancestries inherit different risks and encounter different environmental exposures resulting in different somatic profiles. Research Presented at the American Association for Cancer Research (AACR) Annual Meeting, held April 8-13, 2022 in New Orleans, Louisiana, demonstrates that a lack of knowledge about ancestry-specific alterations is a major barrier…
Harriet Unsworth outlines her role in updating our evidence standards framework for digital health technologies. She also explains how you can share your views as part of our consultation. 12 April 2022 Harriet Unsworth, NICE technical adviser for digital health. Care models are changing all around us. The significant advancement…
The NICE Strategy 2021 to 2026 states our ambition to use real-world data to resolve gaps in knowledge and drive forward access to innovations for patients. To help deliver on this, we have developed the real-world evidence framework. This describes best practices for the planning, conduct, and reporting of real-world…
April 13, 2022 09:50 AM Eastern Daylight Time DALLAS–(BUSINESS WIRE)–Texas Oncology announced today that it has entered into an agreement with Foundation Medicine, a pioneer in molecular profiling for cancer, to provide Texas Oncology care teams with access to its Food and Drug Administration (FDA)-approved blood-based comprehensive genomic profiling (CGP)…
April 13, 2022 Michael Vasconcelles, MD, Brad Jordan, PhD Evidence-Based Oncology, April 2022, Volume 28, Issue 3Pages: SP142-SP143 Recent steps by FDA to promote the use of real-world evidence are to be commended, but the future demands a broader vision that makes greater use of growing sources of health care information. The COVID-19 pandemic…
– Medical chart review study, published in Drugs in Context, evaluated the real-world use of INOmax® (nitric oxide) gas, for inhalation in hospitalized COVID-19 patients with mild-to-moderate acute respiratory distress syndrome (ARDS) in the U.S. – DUBLIN, April 13, 2022 /PRNewswire/ — Mallinckrodt plc (OTCMKTS:MNKKQ), a global biopharmaceutical company, today announced the publication of findings from a retrospective…
Pertuzumab combined with trastuzumab, and docetaxel revealed comparable survival outcomes with previous studies of patients with metastatic breast cancer, including the CLEOPATRA trial. A real-world analysis evaluating the triplet regimen of pertuzumab (Perjeta), trastuzumab (Herceptin), and docetaxel—THP—in Korean patients with metastatic breast cancer (mBC) revealed comparable survival outcomes with previous…
ABSTRACT BACKGROUND: It is not known whether sotrovimab, a neutralizing monoclonal antibody (mAb) treatment authorized for early symptomatic COVID-19 patients, is effective against the SARS-CoV-2 Delta variant to prevent progression to severe disease and mortality. METHODS: Observational cohort study of non-hospitalized adult patients with SARS-CoV-2 infection from October 1 st 2021 –…
LinkDoc Technology Limited, a Chinese medical big data company, announced on Monday that it has withdrawn its application for a public listing in the United States. In June 2021, LinkDoc submitted a prospectus to the Securities and Exchange Commission (SEC) in application for a listing on the Nasdaq. The trading…
Vivalink platform’s ability to deliver uninterrupted streams of real-world physiological data enables faster algorithm development for disease detection and diagnosis CAMPBELL, Calif., April 12, 2022 /PRNewswire/ — Vivalink, a leading provider of digital healthcare solutions, has expanded the use of its Biometrics Data Platform to serve companies developing artificial intelligence (AI) and machine…